Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
Key facts
- Who runs it
- Todd C. Lee MD MPH FIDSA
- Where
- Canada3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 300 people, planned
- Started
- 23 Feb 2026
- Expected to end
- Jan 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Clopidogrel
- Aspirin
- Record updated
- 17 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Patient is taking (or will imminently start) aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease)
Who cannot take part
- Concomitant receipt of an oral factor Xa inhibitor (apixaban, rivaroxaban, or edoxaban) or dabigatran
- Active bleeding (allowing up to 120 hours from platform entry to randomize in the event anti-thrombotic therapy is resumed)
- Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days
- Allergy to clopidogrel
- Pregnancy or lactation
- Known receipt of clopidogrel, prasugrel, or ticagrelor within the last month
Other criteria
- The participant must meet all inclusion and exclusion criteria for the SNAP
- Platform (NCT05137119) and also the following inclusion and exclusion criteria:
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Staphylococcus aureus endocarditis or staphylococcus aureus septicemia or staphylococcus aureus bloodstream infection
This trial is currently available in Canada.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention.
Read full original descriptionShow less
Unlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it.
This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119).
If positive, this study will support a Phase 3 RCT in people who do not currently have an indication for clopidogrel.
The 2 groups in the trial
- Change to clopidogrel 75mg per dayTreatment being tested
Patients will have their aspirin discontinued and start clopidogrel.
Treatment: Clopidogrel
- Continue aspirinExisting treatment, for comparison
Patients will continue their existing aspirin
Treatment: Aspirin
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT06650488, who can take part
- Record updated
- 17 November 2026